Hubei Goto Biopharm Co.,Ltd. (SHE:300966)
China
· Delayed Price · Currency is CNY 15.42
-0.24 (-1.53%)
Apr 25, 2025, 10:45 AM CST
Hubei Goto Biopharm Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Operating Revenue | 536.6 | 565.5 | 604.4 | 588.37 | 464.71 | Upgrade
|
| Other Revenue | - | 0.9 | 0.17 | 2.52 | 3.41 | Upgrade
|
| Revenue | 536.6 | 566.4 | 604.57 | 590.89 | 468.12 | Upgrade
|
| Revenue Growth (YoY) | -5.26% | -6.31% | 2.32% | 26.23% | 0.71% | Upgrade
|
| Cost of Revenue | 431.03 | 450.29 | 466.77 | 446.63 | 362.21 | Upgrade
|
| Gross Profit | 105.56 | 116.11 | 137.81 | 144.26 | 105.9 | Upgrade
|
| Selling, General & Admin | 67.82 | 50.16 | 42.5 | 40.58 | 19.69 | Upgrade
|
| Research & Development | 51.08 | 38.1 | 45.15 | 37.12 | 21.6 | Upgrade
|
| Other Operating Expenses | -11.26 | -3.68 | -0.17 | 1.53 | 1.78 | Upgrade
|
| Operating Expenses | 107.65 | 89.03 | 92.35 | 79.78 | 44.51 | Upgrade
|
| Operating Income | -2.09 | 27.08 | 45.46 | 64.48 | 61.39 | Upgrade
|
| Interest Expense | - | -13.33 | -13.68 | -5.17 | -6.75 | Upgrade
|
| Interest & Investment Income | - | 2.39 | 1.92 | 1.19 | 0.64 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 1.05 | 2.24 | -0.6 | -0.83 | Upgrade
|
| Other Non Operating Income (Expenses) | -30.09 | -0.5 | -0.59 | -0.72 | -0.24 | Upgrade
|
| EBT Excluding Unusual Items | -32.18 | 16.7 | 35.35 | 59.17 | 54.21 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.35 | -0.01 | -0.18 | -1.05 | -0.25 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.11 | 0.17 | -0.01 | - | -0.01 | Upgrade
|
| Asset Writedown | -13.12 | -2.23 | -0.96 | -0.06 | -0.5 | Upgrade
|
| Legal Settlements | - | -0.03 | -0.05 | 0.01 | -0.02 | Upgrade
|
| Other Unusual Items | - | 4.53 | 4.36 | 28.05 | 6.8 | Upgrade
|
| Pretax Income | -45.54 | 19.12 | 38.51 | 86.12 | 60.24 | Upgrade
|
| Income Tax Expense | -13.88 | -2.17 | -1 | 8.05 | 7.05 | Upgrade
|
| Earnings From Continuing Operations | -31.66 | 21.29 | 39.51 | 78.07 | 53.2 | Upgrade
|
| Minority Interest in Earnings | 4.07 | 1.72 | 0.69 | 0.26 | 0.09 | Upgrade
|
| Net Income | -27.59 | 23.01 | 40.21 | 78.33 | 53.29 | Upgrade
|
| Net Income to Common | -27.59 | 23.01 | 40.21 | 78.33 | 53.29 | Upgrade
|
| Net Income Growth | - | -42.78% | -48.67% | 46.99% | -27.00% | Upgrade
|
| Shares Outstanding (Basic) | 115 | 115 | 115 | 106 | 86 | Upgrade
|
| Shares Outstanding (Diluted) | 115 | 115 | 115 | 106 | 86 | Upgrade
|
| Shares Change (YoY) | -0.05% | 0.13% | 8.77% | 22.87% | 0.08% | Upgrade
|
| EPS (Basic) | -0.24 | 0.20 | 0.35 | 0.74 | 0.62 | Upgrade
|
| EPS (Diluted) | -0.24 | 0.20 | 0.35 | 0.74 | 0.62 | Upgrade
|
| EPS Growth | - | -42.86% | -52.81% | 19.63% | -27.06% | Upgrade
|
| Free Cash Flow | -332.2 | -341.12 | -431.98 | -32.91 | -5.09 | Upgrade
|
| Free Cash Flow Per Share | -2.89 | -2.97 | -3.76 | -0.31 | -0.06 | Upgrade
|
| Dividend Per Share | - | 0.016 | - | 0.136 | - | Upgrade
|
| Gross Margin | 19.67% | 20.50% | 22.79% | 24.41% | 22.62% | Upgrade
|
| Operating Margin | -0.39% | 4.78% | 7.52% | 10.91% | 13.11% | Upgrade
|
| Profit Margin | -5.14% | 4.06% | 6.65% | 13.26% | 11.38% | Upgrade
|
| Free Cash Flow Margin | -61.91% | -60.23% | -71.45% | -5.57% | -1.09% | Upgrade
|
| EBITDA | 40.89 | 53.55 | 69.76 | 86.76 | 82.58 | Upgrade
|
| EBITDA Margin | 7.62% | 9.45% | 11.54% | 14.68% | 17.64% | Upgrade
|
| D&A For EBITDA | 42.98 | 26.47 | 24.3 | 22.28 | 21.18 | Upgrade
|
| EBIT | -2.09 | 27.08 | 45.46 | 64.48 | 61.39 | Upgrade
|
| EBIT Margin | -0.39% | 4.78% | 7.52% | 10.91% | 13.11% | Upgrade
|
| Effective Tax Rate | - | - | - | 9.35% | 11.70% | Upgrade
|
| Revenue as Reported | - | 566.4 | 604.57 | 590.89 | 468.12 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.